Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
CTR Vegivinti, KW Evanson, H Lyons, I Akosman… - BMC Infectious …, 2022 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …
threat to public health worldwide. The purpose of this study was to review current evidence …
Efficacy and safety of azithromycin in Covid‐19 patients: A systematic review and meta‐analysis of randomized clinical trials
Azithromycin (AZM) is commonly used in Covid‐19 patients based on low‐quality evidence,
increasing the risk of developing adverse events and antimicrobial resistance. The current …
increasing the risk of developing adverse events and antimicrobial resistance. The current …
[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
Background The antibacterial, anti-inflammatory, and antiviral properties of azithromycin
suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate …
suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate …
Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial
Importance Azithromycin has been hypothesized to have activity against SARS-CoV-2.
Objective To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection …
Objective To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection …
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials
Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded …
PR Martins-Filho, LC Ferreira, L Heimfarth… - The Lancet Regional …, 2021 - thelancet.com
Background Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug
considered a potential candidate for drug repurposing in COVID-19 due to their in vitro …
considered a potential candidate for drug repurposing in COVID-19 due to their in vitro …
Comparison of racial, ethnic, and geographic location diversity of participants enrolled in clinic-based vs 2 remote COVID-19 clinical trials
J Stewart, ML Krows, TT Schaafsma… - JAMA Network …, 2022 - jamanetwork.com
Importance Racial and ethnic diversity among study participants is associated with improved
generalizability of clinical trial results and may address inequities in evidence that informs …
generalizability of clinical trial results and may address inequities in evidence that informs …
Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian …
M Bassetti, DR Giacobbe, P Bruzzi, E Barisione… - Infectious Diseases and …, 2021 - Springer
Abstract Introduction The Italian Society of Anti-Infective Therapy (SITA) and the Italian
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …